The Australian published an article on CBNS CI Associate Professor Kris Thurecht‘s presentation at ASBTE 2018. He is giving a talk about the bio-imaging Signature Project and their breakthrough findings in nanomedicine:
New developments in nanomedicine will be able to precisely measure the effectiveness of minuscule packets of anti-cancer drugs delivered directly to cancerous cells, leaving the rest of the body drug-free.
Flooding a patient’s body with toxic cancer drugs can kill the tumours, but too often they leave the patient desperately ill.
Australian scientists have now found a way to measure exactly how much of the active anti-cancer drug is delivered directly to the cancer cells and where it is delivered, in real time, giving medical experts potentially lifesaving information.
In a scenario echoing the 1960s science-fiction film Fantastic Voyage, the minuscule packets of chemotherapy and other anti-cancer drugs travel through the bloodstream and zero in on the tumour.
Queensland University Associate Professor Kristofer Thurecht, from the ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, will today present data on the new developments at an international conference in Fremantle.
He will show how a combination of chemistry and Magnetic Resonance Imaging and other scans can discern whether the drugs are heading to precisely the right place and at what rate the drugs are getting to the tumour.
Presenting his data to the Australasian Society for Biomaterials and Tissue Engineering Conference, Professor Thurecht will explain why the developments are so important in the treatment of one of the world’s deadliest diseases.
The new developments will potentially take cancer treatments a step closer to personalised medicine, with drug regimes tailored to suit each individual patient.
The article was written by Sian Powell and published in The Australian on 5 April 2018